Compare total cost of care between standard care pathways and Artidis enhanced analysis of breast cancer screening, analysis and treatment.
Standard Care Total
$1,249,846
Annual cost without Artidis
With Artidis Analysis
$988,361
Annual recurring cost with Artidis
Annual Clinical Savings
$261,485
20.9% reduction vs. standard care
Per-Patient Savings
$261
Across 1,000 patients
Time to Treatment Impact
Week 1 = optimal outcomes. Each additional week increases tumor aggressiveness by ~2%, requiring more intensive chemotherapy. Current delay (6 weeks) sets chemotherapy threshold at 28%.
Artidis provides immediate biopsy analysis, enabling faster treatment initiation. Week 1 = maximum savings with 8% cost benefit. Longer delays reduce Artidis advantage.
Potential Savings based on Initial Week of Late Stage Treatment:
Source: Bleicher RJ, et al. "Time to Surgery and Breast Cancer Survival in the United States." JAMA Oncology, 2016. Median time from diagnosis to surgery: 32â62 days depending on treatment type. 6-week standard care default reflects U.S. community-setting midpoint.
Artidis-Guided Chemotherapy Selection
âšī¸ This threshold is automatically adjusted by the Treatment Delay slider (18% at week 1 + 2% per week). Manual adjustments override the automatic calculation.
Sensitivity (Malignant Detection)
Specificity (Risk Assessment)
Capital Equipment
Annual Operating Costs
Staffing & Training
Chemotherapy-Related
Radiation-Related
Annual Savings
$261,485
20.9% reduction
Per Patient Savings
$261
across 1,000 patients
Diagnostic Savings
-$37,962
Screening, biopsy, pathology and workup
No saved scenarios yet
Save your first scenario to compare different configurations